WHIPPANY, NJ--Two new forms of Dilaudid (hydromorphone HCL)--
Dilaudid 8 mg tablets and Dilaudid-5 Oral Liquid--are now available
from Knoll Pharmaceutical Company.
The 8 mg tablets allow easy titration to a higher hydromorphone
dose and are more convenient for patients currently taking two
Dilaudid 4 mg tablets per dose, the manufacturer said.
Dilaudid-5 Oral Liquid is designed for patients who have difficulty
swallowing solid medications. One teaspoon contains 5 mg of hydromorphone
per 5 mL. The liquid is alcohol-free, colorless, unflavored, and
can be mixed with fruit juice, according to Knoll.
In addition, Knoll is making available a pocket guide "Strategies
for Cancer Pain Management," written by Ada Rogers, RN, research
associate and clinical coordinator of the Pain Research Group,
Memorial Sloan-Kettering Cancer Center.
The guide contains general information on opioid use in cancer
pain, as well as specific dosing information on Dilaudid, including
a dose conversion chart. Call 201-575-5656 (9 am to 5 pm EST)
for free copies.